Pain Medicine, Interventional Pain Medicine · Mesquite, TX
NPI
1851351977
Since 2006
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
910 N Galloway Ave # 302
Mesquite, TX, 75149
Phone (972) 301-8897
Groups this clinician bills Medicare through
Medicare paid, 2024
$269K
7,529 services
Medicare patients, 2024
164
Average age 68
Drug cost, 2024
$1.2M
5,089 prescriptions
Company payments, 2025
$4,041
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kashif Irfan was code J2704 (injection, propofol, 10 mg), 1,372 times for 25 patients. In total Kashif Irfan billed 7,529 services in 78 codes, and Medicare paid $269K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2704 Injection, propofol, 10 mg | Office | 1,372 | 25 | $0.09 | $117 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 540 | 47 | $0.76 | $410 |
| 99214 Office E&M - Established | Office | 494 | 123 | $90.48 | $45K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 472 | 140 | $12.26 | $5,786 |
| 80307 Drug Tests | Office | 437 | 128 | $60.42 | $26K |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 436 | 128 | $111.22 | $48K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 307 | 42 | $46.89 | $14K |
| 96138 Behavioral Health Services | Office | 269 | 108 | $26.84 | $7,219 |
| 98977 Pulmonary Function Testing | Office | 230 | 63 | $36.22 | $8,330 |
| 98980 Care Management/Coordination | Office | 227 | 61 | $39.10 | $8,876 |
| 98981 Care Management/Coordination | Office | 172 | 47 | $31.45 | $5,410 |
| 99213 Office E&M - Established | Office | 143 | 76 | $58.82 | $8,411 |
| 96127 Behavioral Health Services | Office | 73 | 23 | $3.47 | $253 |
| 98975 Pulmonary | Office | 46 | 43 | $15.34 | $706 |
| 64483 Nerve Block Injection - Back | Office | 44 | 25 | $283.37 | $12K |
By year: 2022 $328K for 6,685 services; 2023 $297K for 7,656 services; 2024 $269K for 7,529 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80307 Drug Tests | 437 | 128 | $60.42 | $26K |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 436 | 128 | $111.22 | $48K |
Medicare prescription drug claims, 2024
In 2024, the drug Kashif Irfan prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 1,120 prescriptions and refills. In total Kashif Irfan wrote 5,089 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,120 | 1,120 | 166 | $37K |
| Gabapentin Generic | 487 | 521 | 88 | $6,020 |
| Tizanidine Hcl Generic | 380 | 489 | 88 | $4,887 |
| Tramadol Hcl Generic | 290 | 290 | 51 | $3,418 |
| Pregabalin Generic | 262 | 274 | 48 | $9,706 |
| Acetaminophen-Codeine Acetaminophen With Codeine | 255 | 255 | 45 | $8,825 |
| Cyclobenzaprine Hcl Generic | 220 | 222 | 36 | $1,909 |
| Methocarbamol Generic | 189 | 195 | 39 | $12K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 172 | 172 | 31 | $6,834 |
| Buprenorphine Hcl Generic | 155 | 157 | 36 | $7,113 |
| Diclofenac Potassium Generic | 133 | 134 | 40 | $410K |
| Oxycodone Hcl Generic | 114 | 114 | 15 | $2,756 |
| Belbuca Buprenorphine Hcl | 86 | 86 | 26 | $63K |
| Morphine Sulfate Er Morphine Sulfate | 83 | 83 | Under 11 | $2,785 |
| Diclofenac Sodium Generic | 71 | 73 | 16 | $22K |
Brand drugs: 510 claims; generic drugs: 4,579 claims; opioid claims: 2,428.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kashif Irfan $4,041 ($4,041 in general payments such as food, travel and fees) from 20 companies. The largest payer was Forte Bio-Pharma LLC with $833.
| Company | Payments | Amount |
|---|---|---|
| Forte Bio-Pharma LLC | 44 | $833 |
| Boston Scientific Corporation BSX | 34 | $557 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 33 | $485 |
| Spinal Simplicity, LLC | 18 | $327 |
| Curonix LLC | 6 | $289 |
| Abbott Laboratories ABT | 9 | $247 |
| Vertex Pharmaceuticals Incorporated VRTX | 4 | $187 |
| Pfizer Inc. PFE | 16 | $181 |
| Medtronic, Inc. MDT | 3 | $180 |
| Nalu Medical, Inc. | 4 | $167 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.